India, April 28 -- image credit- shutterstock

Dr. Reddy's Laboratories expands its strategic partnership with Sanofi Healthcare India Private Limited (SHIPL) to introduce a novel drug, Beyfortus(R)(nirsevimab), in India.

Beyfortus(R)contains the monoclonal antibody, nirsevimab, in a prefilled injection used for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. It is also administered in children up to 24 months of age, who remain vulnerable to severe RSV disease through their second RSV season.

Under the arrangement, Dr. Reddy's will have exclusive rights from SHIPL to promote and distribute Beyfortus(R)(nirsevimab) in India...